Novartis announced on Friday that the US Food and Drug Administration (FDA) had approved a new pharmaceutical production site for Pluvicto, its new treatment for prostate cancer, based in Indianapolis.

This ultra-modern facility, with a surface area of 6,500 m2, will be entirely dedicated to the manufacture of radioligand therapies. It is the Group's second plant in the United States, after the one in Millburn (New Jersey).

The site should enable the laboratory to meet growing demand in the US market, and even in Canada, since the Italian site in Ivrea is also intended to supply international markets.

The one in Saragossa (Spain) is intended solely to supply markets outside the United States.

With these four production sites, Novartis expects to be able to generate production of some 250,000 doses of radioligands in 2024 and the years to come.

The company points out that it is currently conducting several clinical trials on the efficacy of radioligands in other cancers (breast, colon, lung and pancreas, among others).

Copyright (c) 2024 CercleFinance.com. All rights reserved.